# Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

> **NCT02779283** · PHASE1 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 7 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dasatinib
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Idarubicin
- **DRUG:** Idelalisib
- **DEVICE:** In Vitro Kinase Inhibitor Assay
- **DRUG:** Leucovorin Calcium
- **DRUG:** Methotrexate
- **DRUG:** Methylprednisolone Sodium Succinate
- **DRUG:** Ponatinib Hydrochloride
- **BIOLOGICAL:** Rituximab
- **DRUG:** Ruxolitinib Phosphate
- **DRUG:** Sorafenib Tosylate
- **DRUG:** Sunitinib Malate
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT02779283
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-13
- **Primary completion:** 2018-04-19
- **Final completion:** 2018-09-20
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2020-05-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02779283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02779283, "Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02779283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*